Formation Bio

This account is verified. Learn more

@formationbio

AI-native pharma company, bringing new treatments to patients faster and more efficiently.

New York, NY formation.bio Joined November 2014

30 Following 3.1K Followers 233 Posts

Latest posts 5

Formation Bio @formationbio Oct 28

Tune in around 3:40pm EST to hear @BenjamineYLiu on @tbpn!

TBPN Verified account @tbpn Oct 28

Happy Wednesday. On today's show:

- @markgurman (Bloomberg)
- @zachrash (Coco Robotics)
- @BenjamineYLiu (Formation Bio)
- @AmiramShachar (Upwind)
- @zjasper (Hyperbolic)

See you on the stream.
View quoted post on X

Formation Bio @formationbio Oct 28

Learn more about our new $600M Formation Bio Drug Development Accelerator Fund here.

Ben Liu Verified account @BenjamineYLiu Oct 28

Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund.

@lintaho and I started @FormationBio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development.

As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients.

Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.

View quoted post on X

Formation Bio @formationbio Oct 19

(1/3) Phyla is Formation Bio’s context layer for causal biology. We benchmarked it against Claude Science and GPT-Rosalind on writing full research dossiers for 7 drug target–disease pairs, and the results are in. 99.7% of Phyla’s statements carried a citation, compared to Claude Science: 87% (Claude Science) and 86% (GPT-Rosalind). Phyla never dropped below 99.3% on any pair.

Formation Bio @formationbio Oct 14

“As a company in the era of AI, you should have a thesis for what predictions will happen first, what will happen last, and make sure your company strategy absorbs this as a net tailwind versus a headwind.”

Our thesis: AI will improve drug discovery first, toxicity next, and clinical efficacy last. Our CEO @BenjamineYLiu explores this in his Uneven Frontiers essay – link in comments.

0:55

Formation Bio @formationbio Sep 18

Formation Bio made #7 on @FastCompany's Best Workplaces for Innovators 2026.

This piece highlights one of our internal systems: ARK (AI-ready Repository of Knowledge), our in-house AI platform that connects all internal systems and data across the company. Full write-up here: fastcompany.com/91591991/forma…

Our open roles: formation.bio/careers
Learn more about ARK: formation.bio/blog/ark-mcp-g…

www.fastcompany.com Formation Bio's AI-ready repository of knowledge Formation Bio used AI to make its vast trove of data more readily available to employees, landing the company at No. 7 on Best Workplaces for Innovators 2026.